On the stock market since 2003, it operates in the world of health and science. It has 1,959 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 7% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $6.6B in the vault; even if every debt were paid off, $6.1B would remain.
It pays out $110 per share each year — regular cash for whoever holds the stock.
A loss of $59.7M against $386.0M in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 5 sells against just 0 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, SVA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SVA is a small company that closed last year at a loss. The road back to profit runs through spending discipline.